We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$685M
Cap. Flow %
-13.38%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
2.8 quarters
Top 20 Avg Time Held Equity + Options
2.8 quarters
Avg Time Held Equity only
6.3 quarters
Top 10 Avg Time Held Equity only
2.9 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS icon
Exact Sciences
EXAS
+$122M
2
ACLX icon
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD icon
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS icon
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
2 Miscellaneous 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRAX icon
1
Praxis Precision Medicines
PRAX
$7.02B
$656M 12.82%
2,035,986
+40,000
+2% +$12.4M
2024 Q1
8 quarters
CELC icon
2
Celcuity
CELC
$3.22B
$357M 6.97%
3,127,200
-33,000
-1% -$3.6M
2023 Q4
9 quarters
ASND icon
3
Ascendis Pharma A/S
ASND
$14.9B
$350M 6.84%
1,531,421
+450,000
+42% +$101M
2025 Q2
3 quarters
ROIV icon
4
Roivant Sciences
ROIV
$25B
$230M 4.48%
8,285,461
+300,000
+4% +$7.71M
2025 Q2
3 quarters
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$209M 4.08%
5,258,903
+2,341,269
+80% +$59.9M
2024 Q1
8 quarters
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.18B
$206M 4.03%
2,373,795
-172,596
-7% -$16.8M
2023 Q3
10 quarters
SYRE icon
7
Spyre Therapeutics
SYRE
$8.03B
$191M 3.73%
3,783,225
+714,000
+23% +$26.9M
2023 Q3
10 quarters
NUVL icon
8
DELISTED
Nuvalent
NUVL
$162M 3.16%
1,580,505
-84,600
-5% -$8.62M
2021 Q3
18 quarters
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.18B
$139M 2.72%
4,423,974
-34,000
-0.8% -$980K
2023 Q4
9 quarters
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.37B
$130M 2.54%
1,230,879
-119,546
-9% -$10.6M
2023 Q1
12 quarters
APGE icon
11
DELISTED
Apogee Therapeutics
APGE
$130M 2.53%
1,540,384
-790,267
-34% -$57.4M
2023 Q3
10 quarters
TVTX icon
12
Travere Therapeutics
TVTX
$4.9B
$123M 2.41%
4,142,551
-135,629
-3% -$4.05M
2025 Q2
3 quarters
AMLX icon
13
Amylyx Pharmaceuticals
AMLX
$3.45B
$115M 2.25%
8,284,882
– –
2024 Q3
6 quarters
IMTX icon
14
Immatics
IMTX
$1.1B
$102M 2%
10,383,456
– –
2020 Q3
22 quarters
RLAY icon
15
Relay Therapeutics
RLAY
$3.94B
$97M 1.9%
9,751,141
+7,847,896
+412% +$70.2M
2025 Q4
1 quarter
INBX icon
16
Inhibrx
INBX
$1.33B
$97M 1.9%
1,442,707
-10,000
-0.7% -$742K
2024 Q2
7 quarters
MGTX icon
17
MeiraGTx Holdings
MGTX
$997M
$89.3M 1.75%
10,326,103
– –
2018 Q2
31 quarters
ZYME icon
18
Zymeworks
ZYME
$1.82B
$87.9M 1.72%
3,510,078
+248,228
+8% +$5.87M
2017 Q2
35 quarters
SLDB icon
19
Solid Biosciences
SLDB
$719M
$85.7M 1.68%
11,906,646
+73,107
+0.6% +$470K
2020 Q2
23 quarters
DYN icon
20
Dyne Therapeutics
DYN
$2.98B
$84.6M 1.65%
4,668,839
+1,189,895
+34% +$20.5M
2024 Q3
6 quarters
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.14B
$70.8M 1.38%
7,434,033
+4,271,504
+135% +$33.2M
2025 Q4
1 quarter
ORKA icon
22
Oruka Therapeutics
ORKA
$5.32B
$68.4M 1.34%
1,395,501
-81,000
-5% -$2.82M
2025 Q3
2 quarters
AORT icon
23
Artivion
AORT
$1.06B
$60M 1.17%
1,637,290
-85,000
-5% -$3.35M
2021 Q4
17 quarters
NRIX icon
24
Nurix Therapeutics
NRIX
$2.3B
$57.5M 1.12%
3,710,877
+155,000
+4% +$2.57M
2024 Q4
5 quarters
MRNA icon
25
PUT
Moderna
MRNA
$85.3B
$50.8M 0.99%
+1,000,000
New +$46.7M
2026 Q1
0 quarters
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.